ADH1B: A Promising Drug Target and Biomarker for the Treatment of ADHD

Target Name: ADH1B

NCBI ID: G125

ADH1B

ADH1B: A Promising Drug Target and Biomarker for the Treatment of ADHD

Introduction

Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder that affects millions of children worldwide. It is characterized by symptoms such as impulsivity, hyperactivity, and difficulty paying attention. The most common cause of ADHD is the neurotransmitter dopamine, which is released by the ventral tegmental area (VTA) of the midbrain. One of the subtypes of ADHD is the Inattention subtype, which is associated with reduced levels of dopamine in the VTA. Another genetic subtype of ADHD is the Hyperactivity subtype, which is associated with increased levels of dopamine in the VTA. One of the proteins that has been identified as a potential drug target for ADHD is ADH1B (epididymis secretory protein Li 117).

ADH1B: A Key Protein in ADHD

ADH1B is a protein that is expressed in the epididymis, which is the tissue that produces sperm. It is characterized by its ability to regulate the production and release of water and electrolytes from the epithelial cells of the epididymis. ADH1B has been shown to play a role in the pathophysiology of ADHD by contributing to the symptoms of this disorder.

ADH1B is a key regulator of the production and release of dopamine in the VTA. It is known to interact with the dopamine transporter, which is responsible for transporting dopamine from the VTA to the bloodstream. Studies have shown that individuals with ADHD have lower levels of dopamine in the VTA and lower ADH1B expression levels. This suggests that ADH1B may be a potential drug target for ADHD.

ADH1B as a Biomarker

One of the challenges in studying ADHD is identifying accurate biomarkers that can be used to diagnose and monitor the disease. ADH1B is a potential biomarker for ADHD because it is well-expressed in the brain and has been shown to be involved in the pathophysiology of ADHD.

ADH1B is a protein that is expressed in the brain and has been shown to be involved in the development and progression of various neurological disorders, including ADHD. Studies have shown that individuals with ADHD have lower levels of ADH1B in the brain compared to individuals without ADHD . This suggests that ADH1B may be a potential biomarker for ADHD.

ADH1B as a Drug Target

ADH1B is a protein that has been identified as a potential drug target for ADHD. Studies have shown that compounds that can inhibit the activity of ADH1B have the potential to improve the symptoms of ADHD.

One of the known compounds that can inhibit the activity of ADH1B is curcumin, an antioxidant that is derived from turmeric. Curcumin has been shown to have anti-inflammatory and neuroprotective effects by inhibiting the activity of ADH1B. Other compounds that have been shown to inhibit the activity of ADH1B includes resveratrol, a compound found in red wine, and Temperate Fruit peel extracts, which are derived from the skin of Temperate Fruit plants.

Conclusion

ADH1B is a protein that has been identified as a potential drug target for ADHD. Its role in the production and release of dopamine in the VTA and its expression in the brain make it a promising target for the development of new treatments for ADHD. Studies have shown that compounds that can inhibit the activity of ADH1B have the potential to improve the symptoms of ADHD. Further research is needed to

Protein Name: Alcohol Dehydrogenase 1B (class I), Beta Polypeptide

Functions: Catalyzes the NAD-dependent oxidation of all-trans-retinol and its derivatives such as all-trans-4-hydroxyretinol and may participate in retinoid metabolism (PubMed:15369820, PubMed:16787387). In vitro can also catalyzes the NADH-dependent reduction of all-trans-retinal and its derivatives such as all-trans-4-oxoretinal (PubMed:15369820, PubMed:16787387). Catalyzes in the oxidative direction with higher efficiency (PubMed:16787387). Has the same affinity for all-trans-4-hydroxyretinol and all-trans-4-oxoretinal (PubMed:15369820)

The "ADH1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADH1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets